TransEnterix Announces Enhanced Capability to Perform Micro Incision Robotic Surgery
31 Julio 2017 - 7:30AM
Business Wire
First-ever use of robotics to perform abdominal
surgery with 3mm microlap instrumentation
TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company
that is pioneering the use of robotics to improve minimally
invasive surgery, today announced that surgeons have now performed
the first 3mm micro laparoscopic robotic surgeries in the world
utilizing the Senhance Surgical Robot. 3mm instruments, often
referred to as micro laparoscopy, allow for surgeons to make tiny
incisions that are deemed virtually scarless for patients.
The surgeries were performed at CHU Saint-Ètienne in France, and
at the Policlinico A. Gemelli Foundation in Rome, Italy. Professor
Celine Chauleur and Dr. Salvatore Gueli Alletti, gynecologic
oncologists, and Dr. Gabriele Barabino, a general surgeon, were the
first surgeons in the world to utilize micro laparoscopic
instruments with an abdominal robotic surgery platform. The
surgeons successfully performed multiple cases in gynecologic and
general surgery such as; ovarian cystectomy, endometrial excision,
total laparoscopic hysterectomy, bilateral salpingo-oophorectomy
and cholecystectomy utilizing robotic microlap instruments.
“Microlaparoscopy with robotic assistance is now a reality
utilizing Senhance,” said Todd M. Pope, President and CEO at
TransEnterix. “The use of microlaparoscopy is a growing trend, but
it can be challenging to manually control and stabilize such small
instruments. We believe Senhance robotic assistance can enable
surgeons to expand their use of virtually scarless surgery in more
patients, and creates an additional way robotics can bring value
over traditional manual approaches.”
“Patients are consistently interested in the least invasive
approach possible,” said Dr. Barabino. “Utilizing 3mm microlap
instruments with the Senhance Surgical Robot creates a virtually
scarless approach with the precision of robotics to control such
small instruments with delicate haptic force feedback.”
About TransEnterix
TransEnterix is a medical device company that is pioneering the
use of robotics to improve minimally invasive surgery by addressing
the clinical and economic challenges associated with current
laparoscopic and robotic options. The company is focused on the
commercialization of the Senhance Surgical Robotic System, a
multi-port robotic system that brings the advantages of robotic
surgery to patients while enabling surgeons with innovative
technology such as haptic feedback and eye sensing camera control.
The company is also developing the SurgiBot™ System, a single-port,
robotically enhanced laparoscopic surgical platform. The Senhance
Surgical Robotic System has been granted a CE Mark, and is
currently under FDA review for clearance in the United States. For
more information, visit the TransEnterix website at
www.transenterix.com.
Forward Looking Statements
This press release includes statements relating to the Senhance™
Surgical Robotic System and our current regulatory and
commercialization plans for this product. These statements and
other statements regarding our future plans and goals constitute
"forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control and which may cause results to differ materially from
expectations and include whether Senhance robotic assistance can
enable surgeons to expand their use of virtually scarless surgery
in more patients, and creates an additional way robotics can bring
value over traditional manual approaches. For a discussion of the
risks and uncertainties associated with TransEnterix's business,
please review our filings with the Securities and Exchange
Commission (SEC), including our Annual Report on Form 10-K filed on
March 7, 2017 and our other filings we make with the SEC. You are
cautioned not to place undue reliance on these forward looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the origination date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170731005521/en/
For TransEnterix, Inc.Investor Contact:Mark Klausner,
+1-443-213-0501invest@transenterix.comorMedia Contact:(For
EU) Conrad Harrington, +44 (0)20 3178 8914(For US) Hannah Dunning,
+1-415-618-8750TransEnterix-SVC@sardverb.com
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024